Before oral-fluid drug screens can be widely accepted, additional efforts must be made to educate their users on the difference between oral-fluid tests and urine tests, emphasizing the shorter windows of detection for various drugs and the fact that the detectable molecules are parent drugs instead of metabolites for some drugs. Cut-off concentrations must be studied further to ensure that food or other ingestibles do not cause false-positive results.
For manufacturers of on-site drug screens, the challenge is to increase the sensitivity of the A-9-tetrahydrocannabinol so that a longer window of detection can be established. Once these challenges are met, oral-fluid drug screens can garner a substantial share of the drug-testing market.
Was this article helpful?